DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim 1 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. In particular there is no mention in the specification for “wherein the leaflets comprise curved portions produced by folding of the sheet”.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 7-8, 12-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3 of U.S. Patent No. 12,102,527 (hereafter ‘527)in view of DeStefano 2013/0144382 (hereafter ‘382). For example, regarding current claims 7 and 8 recites:
7. (New) A prosthetic heart valve comprising: a valve frame having a supporting section and a valve section; and a single continuous sheet of biological material attached to the valve frame, the sheet forming a cylindrical cuff secured to the supporting section and folded inward into the interior of the valve frame to define a plurality of valve leaflets and
commissures as an integral structure, wherein the valve leaflets comprise curved portions produced by the folding of the sheet, and wherein the biological material is secured to the valve frame using a limited number of sutures.
8. (New) The prosthetic heart valve of claim 7, wherein the plurality of valve leaflets comprises two or three leaflets.
Claim 1 of ‘527 recite:
“1. A biological low profile balloon expandable prosthetic heart valve, particularly aortic for transcatheter implantation comprising: a valve frame of cylindrical design which consists of a valve section, along with a supporting section; and a single continuous cylindrical biological material sewn to the valve frame wherein an upper part of the cylindrical biological material is folded into a cuff and is attached to the valve frame supporting section on an outside of the frame and the cuff is folded into the interior of the frame wherein the cuff is attached to posts in the valve section, and the upper parts of the cuff which are not attached to the posts, on each side of the post are connected with each other on the valve frame establishing commissures thereby forming valve leaflets.”
It is obvious to one having ordinary skill in the art that the current claim 7 is broader in scope. However pat. ‘527 does not recite “wherein the leaflets comprise curved portions produced by folding of the sheet”. DeStefano teaches a natural tissue heart valve which utilizes a tissue of material form three leaflets and wherein the leaflet portions are curved. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify pat. ‘527 to have curved portions in order to conform to the curvature of the frame support.
Regarding claim 12, it is obvious to one having ordinary skill in the art that a cuff along the supporting section is configured to seal upon implantation.
Regarding claim 13, DeStefano utilizes a suture e.g. 27 to form a joint at the base of the leaflets. It would be obvious to modify ‘527 to use a continuous suture line in order to avoid disruption and provide a seamless durable implant.
Regarding claim 14, see claim 1 of pat. ‘527;
Regarding claims 15 and 16 pat. ‘527 recites the use of suture and does not limit the amount of suture that may be utilized.
Regarding claims 17-18, DeStefano utilizes pericardial tissue [0021].
Regarding claim 19 treating biological materials by chemical to improve durability is a well-known.
Regarding claim 20 see claim 1 of pat. ‘527. Regarding claim 21 DeStefano teaches a cylindrical lattice structure (see fig. 2).
Regarding claim 22 DeSefano teaches a frame made of shape memory material such as nickel titanium [0023] and is capable of maintain a fixed axial length during expansion. It would be obvious to modify pat. 527 to provide the frame to maintain a fixed axial length during expansion in order to properly fill and fit into the surrounding heart valve tissue.
Allowable Subject Matter
Claims 10-11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
The following is a statement of reasons for the indication of allowable subject matter: The closest prior art has been disclosed supra however does not teach or disclose in combination with claim 7 that the commissures are formed using a surgical suture having two ends alternately passed through opposing leaflet edges; or that a protrusion is formed on the suture between the leaflet edges.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzette Gherbi whose telephone number is (571)272-
4751. The examiner can normally be reached on Monday-Friday 7:00am-3:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http:/Avww.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Melanie Tyson can be reached on 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https:/Awww.uspto.gov/patents/apply/patent- center for more information about Patent Center and https:/Awww.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197.
/SUZETTE J GHERBI/Primary Examiner, Art Unit 3774 September 23, 2026